Adrian Rawcliffe, a director at Wave Life Sciences (NASDAQ:WVE), exercised and sold 42,000 shares on December 8, 2025, in a transaction valued at roughly $630,000. The sale was disclosed in a recent SEC Form 4 filing.
The transaction involved the exercise of vested options and the immediate sale of the resulting shares on the open market. All shares were held directly by Rawcliffe, with no indirect entities involved. Following the sale, his direct holdings stand at 12,700 shares, valued at approximately $235,204 based on the market close price that day.
The filing indicates the transaction was derivative-based, stemming from the conversion of options. It was executed as part of a Rule 10b5-1 trading plan adopted earlier in the year, a common mechanism for pre-scheduled insider transactions.
Wave Life Sciences, a clinical-stage biotechnology company, focuses on developing stereopure oligonucleotide therapeutics for rare genetic diseases. The company utilizes its proprietary PRISM platform and operates through a collaboration-driven model.
As of the market close on December 8, 2025, the company's stock price was $18.52. Wave Life Sciences reported a market capitalization of $2.64 billion, with trailing twelve-month revenue of $109.2 million and a net income of negative $121.9 million.